Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~3.1.1 Age \> 5 years and \< 55 years. NOTE: Subjects ages 5-30 are eligible to be treated at Cincinnati Children's Hospital Medical Center; subjects over age 30 will be treated at Ohio State University Comprehensive Cancer Center.~3.1.2 Anticipated life expectancy of at least nine months 3.1.3 Karnofsky score \> 50 for patients \> 10 years of age, and Lansky score \> 50 for patients \< 10 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.~3.1.4 Patients must have one of the following newly-diagnosed central nervous system tumors, confirmed by histologic verification: Glioblastoma multiforme (WHO grade IV) OR Anaplastic astrocytoma (WHO grade III)~3.1.5 Patients older than 30 years that have undergone a gross total resection and who do not have measurable disease on post operative MRI; measurable disease as assessed by post operative MRI is required on patients 30 years of age or younger.~3.1.6 Neurologic deficits and corticosteroid doses must be stable or decreasing at the time of study entry.~3.1.7 Adequate organ function as defined by: Serum creatinine \< upper limit of normal, or GFR \> 70 ml/min/1.73 m2 Total bilirubin \< 2.0 mg/dl; SGPT (ALT) AND SGOT (AST) \< 2.5x upper limit of normal; serum albumin \> 2.0 g/dL Absolute neutrophil count \> 1,000/µl, platelet count \> 75,000/µl independent of transfusions~3.1.8 The patient and/or the patient's legally authorized guardian must give written informed consent according to local Institutional and/or University Human Experimentation Committee requirements.~3.1.9 Women or men with reproductive potential must use effective contraception throughout the study. Effective contraception methods for women would include either an oral or transdermal contraceptive, injectable contraceptive (e.g., Depo-Provera), or contraceptive implants (e.g., intrauterine device). All males on study must agree to the use of condoms during intercourse.~3.1.10 Women of reproductive potential must have a negative serum pregnancy test.~Exclusion Criteria:~3.2.1 Any prior treatment with chemotherapy or radiotherapy.~3.2.2 Any tumor arising in the spine or brainstem.~3.2.3 Presence of metastatic disease in the spine.~3.2.4 WHO grade III oligodendroglioma or oligoastrocytoma.~3.2.5 Active infection at time of study entry.~3.2.6 Pregnant or lactating females are excluded, because of the known teratogenic effects of alkylating agents.~3.2.7 Known HIV-positive patients. Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy and are excluded from this study. An infectious disease screen consisting of HIV I \& II Ab and NAT, HTLV I \& II Ab, RPR, Hepatitis B Surface Ag, Hepatitis B Core Ab and Hepatitis C Ab will be obtained at study entry.~3.2.8 Concurrent treatment with other investigational anti-cancer agents.~3.2.9 Serious illness or medical condition which would not permit the patient to be managed according to the protocol.~3.2.10 Low-grade glioma (WHO Grade 1-2).

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues